JP6229550B2 - Urinal and trap unit - Google Patents

Description

  The present invention relates to a urinal and a trap unit that form sealed water with urine.

Washing-type urinals that maintain hygiene by supplying water after each use are widely used. Human urine contains various germs, and if urine remains in the bowl of a urinal after use, the germs in the urine further grow with time. Furthermore, by decomposing urea in urine and generating ammonia, ammonia odor and urine stone (solid materials such as calcium phosphate and magnesium phosphate derived from urine-containing components) are generated. For this reason, in a general flush toilet, the urine remaining in the bowl is washed away by discharging water into the bowl of the urinal.

  In addition, in this conventional flush toilet, the water is discharged into the bowl, so that the water flows into the trap connected downstream of the bowl, and the stored urine is replaced with the water and discharged. doing. Furthermore, the urine remaining in the drain pipe connected downstream of the trap is washed away with water supplied from the bowl through the trap. Thereafter, the discharge of water is finished in a state where the trap is filled with water. As a result, the urine remaining in the bowl, etc., is washed away before the bacteria in the urine grow significantly, suppressing the generation of ammonia and the generation of urinary stones, preventing the generation of odors and clogging of drainage pipes due to urinary stones ing. The water that fills the trap functions as a sealing water and prevents the backflow of odor from the drain pipe. Since there is only water in the trap after washing, even if the sealed water in the trap volatilizes and diffuses into the toilet room where the urinal is installed, the volatile component does not cause odor.

  In recent years, water-saving performance has been demanded for equipment using such water in response to the growing environmental awareness. High water-saving performance is also required for flush toilets as described above, and efforts are being made to reduce the amount of water used after use.

  As an example of a urinal corresponding to a request for saving water, a non-flush type urinal having a trap as disclosed in JP-T-2007-518005 (Patent Document 1) is known. A general flush toilet supplies water every time after use and uses water stored in the trap as sealed water, whereas a non-flush type urinal with a trap disclosed in JP-T-2007-518005 In the toilet bowl, water is not basically supplied after use, and urine stored in the trap is used as sealing water.

When the urine stored in the trap is used as sealing water, ammonia volatiles due to decay of the urine and diffusion into the toilet room, and urine stones are generated in the trap and in the pipe There is a concern to do. In response to this concern, in the trap disclosed in Japanese Patent Publication No. 2007-518005, the problem is solved by installing a medicine on the trap or in the vicinity of the connection between the trap and the pipe. A drug such as citric acid is disposed on the trap, and the drug dissolved by contact with urine flows into the trap together with the urine. Further, a medicine such as citric acid is also arranged at a position where the urine is discharged into the pipe, and the medicine dissolved by the contact flows into the pipe together with the urine.

Special table 2007-518005 gazette

However, non-washing urinals as described in JP-T-2007-518005 do not flow water after use. Therefore, the drug dissolves only when urine is applied to the drug when the urinal is used. Therefore, when the use frequency of the urinal is low, it becomes difficult for the medicine to flow into the trap unit. As a result, the urine in the trap is easily spoiled, and ammonia odor is generated, and urinary stones are easily generated in the trap and the pipe.

As a method for stably dissolving the drug in the trap unit, it is considered that the drug is placed in the trap and immersed in urine. However, if the drug is left immersed in urine, the surface area of the drug in contact with urine decreases as the drug dissolves. Thereby, there exists a problem that the melt | dissolution rate of a chemical | medical agent becomes low. When the dissolution rate is low, it becomes difficult to prevent the generation of ammonia odor from the trap unit and the generation of urinary calculus in the trap unit or pipe for a long period of time.

Accordingly, an object of the present invention is to keep the dissolution rate of a drug constant and prevent the generation of ammonia odor from the trap unit and the generation of urinary calculus in the trap unit or piping for a long period of time.

In order to achieve the above object, according to the present invention, in a urinal having a trap unit that forms a sealed water by urine, a solid medicine containing a material that suppresses the production of urinary stones is disposed in the trap unit. And the medicine has a first surface, a second surface facing the first surface, and a side surface connecting the first surface and the outer periphery of the second surface, The side surfaces are characterized by being covered with a water-insoluble material so that urine does not come into contact therewith.

  ADVANTAGE OF THE INVENTION According to this invention, it becomes possible to keep the dissolution rate of a chemical | medical agent constant, and to prevent generation | occurrence | production of the ammonia smell from the inside of a trap unit, and generation | occurrence | production of the urine stone in a trap or piping.

It is the schematic which shows an example of the urinal which can be used by this invention. It is sectional drawing of FIG. It is sectional drawing of the trap unit which concerns on embodiment of this invention. It is the schematic of the chemical | medical agent which concerns on embodiment of this invention. It is the schematic of the chemical | medical agent which concerns on embodiment of this invention. It is the schematic of the trap unit which concerns on embodiment of this invention. It is a figure which shows the result of the durability test which concerns on the Example of this invention.

  Hereinafter, the present invention will be described in detail.

(urinal)
The urinal according to the present invention is a urinal having a trap unit that forms a sealed water by urine, and a solid medicine containing a material that suppresses the production of urinary stones is disposed in the trap unit, The medicine has a first surface, a second surface facing the first surface, and a side surface connecting the first surface and the outer periphery of the second surface, and the side surface is urine It is characterized by being covered with a poorly water-soluble material so as not to contact.

First, the urinal US which can be used in the present invention will be described with reference to FIGS. FIG. 1 is a schematic view showing a front view of the urinal US. The urinal shown here is merely an example, and the urinal of the present invention is not limited to this.

The urinal body 10 is installed with its back surface in contact with a wall WL such as a toilet room. The urinal body 10 is formed of a material and a forming method that can be formed into an arbitrary shape such as pottery or a resin material.

The urinal body 10 includes a bowl portion 103 and a trap unit 30 that forms a sealed water with urine. The bowl portion 103 is a portion that receives urine discharged by the user in a standing posture. The bowl portion 103 has a standing wall portion 104 and a bottom surface portion 105. The standing wall portion 104 is a portion that faces the user in the stool and directly receives the urine, and is a wall-shaped portion that extends vertically and horizontally. A bottom opening 106 is formed in the bottom portion 105. The bottom surface portion 105 is a portion that guides the urine that is received by the standing wall portion 104 and flows downward to the bottom surface opening portion 106 that is a drain port, and is a floor-shaped portion that extends in the front-rear and left-right directions. The urine guided to the bottom opening 106 by the bottom part 105 passes through the trap unit 30 from the bottom opening 106 and is discharged to the drain pipe WT outside the bowl part 103. The trap unit 30 used in the present invention will be described later.

The urinal body 10 may include a nozzle cover 101, a human body detection sensor 102, and a sanitation maintenance device 20. An example of a preferable mode when the urinal body 10 includes these will be described below.

The nozzle cover 101 is a cover for covering a nozzle unit 202 and a bowl drying fan 203 described later. The nozzle unit 202 and the bowl drying fan 203 are preferably arranged above the urinal body 10. Therefore, it is preferable that the nozzle cover 101 is also disposed above the urinal body 10.

  The human body detection sensor 102 is a sensor for detecting a user who uses the urinal US. The human body detection sensor 102 is preferably provided on the back side near the center of the bowl portion 103. The human body detection sensor 102 is preferably a sensor using a microwave. The human body detection sensor 102 irradiates the microwave through the standing wall 104 and reflects the reflected wave returning from the user's body to indicate that the user is in use or has finished using the urinal. What can detect that it left US is preferable.

As the sanitation maintenance device 20, a device having a control unit 201, a nozzle unit 202, and a bowl drying fan 203 can be used. The hygiene maintenance device 20 is preferably provided on the back side of the urinal body 10. The control unit 201 outputs a control signal for driving the nozzle unit 202 and the bowl drying fan 203.

The nozzle unit 202 is preferably provided above the standing wall 104 of the bowl 103 and discharges the liquid supplied from the control unit 201 into the bowl 103. When the nozzle unit 202 discharges the liquid agent to the bowl portion 103, it is possible to suppress the generation of ammonia odor and urine stone using urine present on the surface of the bowl portion 103 as a generation source. The liquid agent contains a chemical solution that suppresses the generation of ammonia odor and urine stones that use urine present on the surface of the bowl portion 103 as a generation source. It is preferable that a thin plate-like nozzle cover 101 is provided on the front surface of the nozzle unit 202 to cover the nozzle unit 202 so that it cannot be seen by the user, thereby improving the design.

The bowl drying fan 203 is preferably provided above the standing wall 104 of the bowl 103 and is covered by the nozzle cover 101. By driving the bowl drying fan 203, the bowl 103 can be dried by blowing air into the bowl 103.

(Trap unit)
The trap unit used in the present invention will be described with reference to FIG. As shown in FIG. 3, the trap unit 30 has a body portion 301 and a bottom surface 302.

  The trap unit 30 is provided below the bottom opening 106 that is a drain outlet. The trap unit 30 has an opening through which urine discharged from the bottom opening 106 flows into the trap unit 30. Further, the trap unit 30 has a trunk portion 301 for storing the urine that has flowed in. The trap unit 30 is configured to store the flowed urine and form a sealed water with the urine. The trunk portion of the trap unit 30 is provided with a discharge port, and urine that can no longer be stored in the trap unit 30 is discharged from the discharge port. The trap unit 30 preferably stores an amount of urine so that the drug 31 is immersed in the urine, and for this purpose, the discharge port is preferably provided above the trunk portion. The urine discharged from the discharge port is discharged to the drain pipe WT. By using urine as sealed water in this way, backflow of odor from the drain pipe WT connected downstream of the trap unit 30 is prevented. The trap unit 30 is installed by being inserted into the bottom opening 106 and is configured to be replaceable. Since the trap unit 30 can be replaced, urine stones are generated in the trap unit 30, and even if a drainage failure occurs, the drainage performance can be restored by replacing the trap unit 30.

  Examples of the shape of the trap unit 30 include a cylinder, a triangular prism, and a quadrangular prism. For example, when the shape of the trap unit 30 is a cylinder, the portion formed by the side surface of the cylinder is the body portion 301 in the present invention, and the circle that is the bottom surface of the cylinder is the bottom surface 302 in the present invention. When the shape of the trap unit 30 is a cylinder, the medicine 31 can be easily placed in the trap unit 30.

The material constituting the trap unit 30 is not particularly limited as long as it is difficult to dissolve in water, has strength as a structure, and is strong against acid. Specific materials include resin and ceramics. As the resin, known resins such as polypropylene (PP), polymethyl methacrylate (PMMA), polycarbonate (PC), polyethylene (PE), polyvinyl alcohol (PVA), polylactic acid, epoxy resin, and polyester resin can be used. .

Further, a guide 303 for arranging the medicine 31 may be provided in the trap unit 30. The guide 303 is for holding the medicine 31 in the trap unit 30 and is configured so that the medicine 31 can be arranged on the guide 303. The guide 303 is preferably provided on the inner wall of the body portion 301 of the trap unit 30. Specific examples of the guide 303 include a configuration in which several convex portions are provided on the inner wall of the body portion 301 of the trap unit 30 and a configuration in which convex portions are provided so as to cover the inner periphery of the inner wall of the trap unit 30. Can be mentioned. The guide 303 is preferably provided in the vicinity of the bottom surface of the trap unit 30 in order to increase the size of the medicine 31 that can be arranged in the trap unit 30 as much as possible.

The guide 303 is preferably configured such that urine flows smoothly through the trap unit 30. For example, the structure which provided the communicating hole for urine to pass through to the guide 303 is mentioned. As an example of a specific configuration, a configuration in which a hole communicating with the convex portion is provided in the above-described convex portion can be given. The number and size of the holes can be determined in consideration of the size of the medicine to be arranged and the amount of urine flowing through the trap unit 30. When providing a hole in the guide 303, the medicine 31 is arranged so as not to block the hole provided in the guide 303. By providing a hole in the guide 303, urine that has flowed into the trap unit 30 enters under the medicine 31 through the hole in the guide 303, or urine that exists under the medicine 30 passes through the hole in the guide 303. It is possible to discharge from a discharge port provided in the trap unit 30.

In the present invention, the urine stored in the trap unit 30 is preferably maintained at a pH of 3 or more and 8 or less. By setting the pH to 3 or more, corrosion of the pipe WT can be prevented. In addition, by controlling the pH to 8 or less, non-volatile ammonium ions (NH ₄ ⁺ ) are prevented from changing to volatile ammonia (NH ₃ ), and ammonia is prevented from diffusing into the air. Can do. In the present invention, it is more preferable to maintain the pH in the trap unit at 3 or more and 7 or less. By adjusting the pH to 7 or less, it becomes possible to suppress the production of urine stone.

(Drug)
In the trap unit 30 of the present invention, a solid medicine 31 containing a material that suppresses the production of urine stone is disposed. The medicine has a first surface 33, a second surface 34 that faces the first surface 33, and a side surface 32 that connects the first surface 33 and the outer periphery of the second surface 34. The side surface 32 is covered with a hardly water-soluble material. With such a configuration, the first surface 33 and the second surface 34 come into contact with urine and dissolve. As drug 31 comes into contact with urine and dissolves, the surface area of the drug in contact with urine gradually increases. Therefore, it is possible to keep the dissolution rate of the medicine constant and prevent the generation of ammonia odor from the trap unit and the generation of urine stone in the trap unit for a long time.

The figure shows specific examples of drugs used in the present invention. FIG. 4 shows a quadrangular column medicine, in which the side surface 32 is covered with a poorly water-soluble material. FIG. 5 shows a cylindrical drug, and the side surface 32 is covered with a poorly water-soluble material.

As the drug 31 comes into contact with the urine and dissolves, the surface area of the drug in contact with the urine gradually increases, and the reason why the drug dissolution rate can be kept constant is considered as follows. It is not limited to. The dissolution rate of the drug 31 can be obtained from a dissolution rate equation (Noyes-Whitney equation). The dissolution rate equation is represented by dC / dt = k * S (Cs−C). Here, dC / dt is the dissolution rate, C is the concentration of the solution after time t, k is the apparent dissolution rate constant, Cs is the solubility of the solid, and S is the surface area of the solid. Here, in this specification, “solid” is regarded as a drug, and “solid surface area” is regarded as a surface area of a drug in contact with urine. From this equation, it can be seen that the dissolution rate is proportional to the surface area of the drug 31 in contact with urine. That is, the dissolution rate increases as the surface area of the drug 31 in contact with urine increases. On the other hand, the dissolution rate of the drug is inversely proportional to the amount of urine in the trap unit 30. That is, the dissolution rate decreases as the amount of urine present in the trap unit 30 increases. This is because if the volume of urine in the trap unit 30 is large, the concentration of the drug in the trap unit 30 becomes difficult to be uniform, and the apparent dissolution rate constant becomes small. As the urinal is used, the volume of the drug decreases by the amount dissolved. As a result, a space is created in the trap unit 30, and the volume of urine in the trap unit 30 increases. Thereby, as the urinal is used, the amount of urine collected in the trap unit increases, and the apparent dissolution rate constant decreases. Therefore, there exists a possibility that the melt | dissolution rate of a chemical | medical agent may fall. However, the medicine 31 of the present invention has a first surface 33, a second surface 34 that faces the first surface 33, and a side surface 32 that connects the first surface 33 and the second surface 34. The side surface 32 of the medicine is covered with a poorly water-soluble material. That is, the side surface 32 of the medicine is configured not to come into contact with urine, and the first surface 33 and the second surface 34 of the medicine 31 come into contact with urine and dissolve. Therefore, as the drug 31 comes into contact with urine and dissolves, the amount of urine in the trap unit increases, so even if the apparent dissolution rate constant decreases, the surface area of the drug in contact with urine gradually increases. It is considered that the dissolution rate of the drug 31 can be kept constant.

Since the trap unit 30 is sealed with urine, the medicine 31 disposed in the trap unit 30 is immersed in urine. Therefore, it is considered that the drug 31 is in contact with urine and the drug 31 is dissolved unless the drug 31 is dissolved and disappears by contact with urine regardless of the frequency of use of the urinal. Thereby, generation | occurrence | production of ammonia odor and generation | occurrence | production of the urine stone in the trap unit 30 or the piping WT can be suppressed.

In the present invention, the drug 31 may have the side surface 32 and the first surface 33 or the second surface 34 covered with a hardly water-soluble material. Thereby, the surface area of the medicine that comes into contact with urine can be reduced, and the effect of the medicine can be obtained for a long time.

In the present invention, the drug 31 may have the side surface 32 and the second surface 34 covered with a water-insoluble material, and the first surface 33 may face the bottom opening 106. Thereby, the surface of the 1st surface 33 which is not covered with a poorly water-soluble material can make it easy to contact urine. Therefore, as the drug 31 comes into contact with the urine and dissolves, the surface area of the drug that comes into contact with the urine gradually increases, so that the dissolution rate of the drug 31 can be kept constant.

As shown in FIG. 6, the medicine 31 used in the present invention may be covered with a trap unit 30 formed of a poorly water-soluble material. In this case, the medicine 31 and the trap unit 30 are covered so that there is no gap between them. It is preferable that the side surface 32 of the medicine 31 and the first surface 33 or the second surface 34 are covered with the trap unit 30. More preferably, the side surface 32 of the medicine 31 is covered with the body portion 301 of the trap unit 30, and the first surface or the second surface of the medicine 31 is covered with the bottom surface. Further, the side surface 32 and the second surface 34 of the medicine 31 may be covered with the trap unit 30, and the first surface 33 may face the bottom surface opening 106.

The shape of the medicine 31 used in the present invention may be a cylinder, a triangular prism, a quadrangular prism, or the like, and is not particularly limited. In the case of a cylinder, it is easy to arrange in the trap unit 30.

(Drug material)
The material of the medicine 31 used in the present invention includes a material that suppresses the production of urine stone and a water-insoluble material that covers the surface. It is preferable that any one or more of an acid, a disinfectant, and a microorganism is included as a material that suppresses the production of urine stone.

By including an acid as a material that suppresses the formation of urine stone, the activity of urease present in the trap unit 30 is suppressed, and urea is not easily decomposed into ammonia. Thereby, generation | occurrence | production of ammonia can be suppressed. Moreover, even if ammonia is generated, ammonia can be neutralized, so that the pH in the trap unit can be kept low.

The saturated solubility of the acid is preferably 0.5 mg / ml or more and 20 mg / ml or less. In the present invention, the drug is immersed in urine. Therefore, by using an acid having such saturation solubility, it is possible to prevent the medicine from being completely dissolved in the trap unit in a short period of time, and to maintain the performance for a long period of time. Further, it is possible to obtain a saturated solubility capable of neutralizing the generated ammonia. Specific examples of preferred acids include phthalic anhydride, phthalic acid, fumaric acid, benzoic acid, edetic acid and the like.

It is preferable that a disinfectant is included as a material that suppresses the production of urine stone. By including a bactericidal agent, it is possible to kill germs contained in urine and suppress the generation of ammonia. When using only a disinfectant as a material that suppresses the formation of urine stone, it is preferable that the saturation solubility is 20 mg / ml or less as in the case of acid. Thereby, it is possible to prevent the medicine from being completely melted in the trap unit in a short period of time.

It is preferable that microorganisms are included as a material that suppresses the production of urine stones. By including microorganisms, ammonia generated in the trap unit 30 is assimilated, and the amount of ammonia in the trap unit 30 is suppressed. As a result, generation of ammonia odor and urinary stones can be suppressed. Specific microorganisms include Bacillus bacteria.

In the medicine 31 used in the present invention, the hardly water-soluble material is a material that is hardly soluble in water or a material that is not soluble in water. The solubility of the hardly water-soluble material is preferably lower than the solubility of the drug used. It is preferable that the hardly water-soluble material does not disappear before the material that suppresses the production of urinary stone dissolves and disappears by contact with urine. Therefore, it is preferable that there is a difference between the solubility of the hardly water-soluble material and the solubility of the material that suppresses the formation of urine stone. A preferable material is a resin. More specific materials include epoxy resins and polyester resins.

As a material of the medicine 31 used in the present invention, a surfactant, a fragrance and the like may be included. By including a fragrance, even if an ammonia odor is generated, the odor can be masked.

(Combination of drugs)
In the present invention, an auxiliary drug may be used in combination with the drug 31 used in the present invention. The auxiliary drug is not particularly limited as long as it does not interfere with the effect of the drug 31 used in the present invention. Materials that can be included in auxiliary agents include surfactants, fragrances, Bacillus subtilis, deodorants, coloring agents, emulsifying and solubilizing agents for oily components, chelating agents, extenders, solubility modifiers, bleaching agents , Water repellents, fillers, pH adjusters, thickeners, drug stability improvers, moldability improvers, inorganic builders, organic builders, enzymes and the like. Examples of the surfactant include an anionic surfactant, a cationic surfactant, an amphoteric surfactant, and a nonionic surfactant. Examples of the fragrances include plant fragrances, animal fragrances, and synthetic fragrances. A material to be used can be appropriately selected according to the purpose of using the auxiliary drug. The auxiliary drug can be obtained by mixing selected materials and molding them into a desired shape. The shape of the auxiliary medicine is not particularly limited as long as it can be arranged in the trap unit 30. The auxiliary medicine may be arranged anywhere in the trap unit 30 as long as it is arranged so as not to interfere with the effect of the medicine 31 used in the present invention. For example, it may be arranged on the bottom surface 302 in the trap unit 30 so as not to contact the medicine 31 used in the present invention.

(Production method)
The method for producing a drug used in the present invention includes a step of obtaining a molded body by molding a material that suppresses the production of urolith into a desired shape, a step of covering the side surface of the molded body with a non-water-soluble material, and a step of producing a drug. Have.

The method for mixing the material for suppressing the production of urine used in the present invention is not particularly limited as long as the materials can be mixed. Known methods such as a stirrer, a mixer, a ball mill, and a jet mill can be used.

The method for molding the material for suppressing the formation of urine used in the present invention is not particularly limited as long as the material can be molded into a desired shape. Examples of the molding method include kneading (extrusion) molding, compression molding, tableting molding, and melt-solidification molding. Among these, since the amount of the same medicine can be made the smallest volume, compression molding is preferable.

  In the present invention, examples of the method for covering the surface of the molded body with a poorly water-soluble material include the following methods. In the method of coating the surface of the molded body with a poorly water-soluble material, and when the trap unit 30 is formed of the poorly water-soluble material, the side surface 32 of the medicine 31 and the first surface 33 or the second surface 34 30.

  As a method of coating the surface of the molded body with a poorly water-soluble material, a known method such as spray coating, dip coating, roll coating, brush coating, etc. is used for the coating composition capable of forming a film of the hardly water-soluble material. Can do. Among these, brushing is preferable because coating is easy.

  In the present invention, when the trap unit 30 is formed of a poorly water-soluble material, a method in which the side surface 32 of the drug and the first surface 33 or the second surface 34 are covered with the trap unit 30 can be used. Specifically, the inner wall of the trunk portion 301 of the trap unit 30 and the side surface of the molded body are brought into close contact with each other, and the inner wall of the bottom surface 302 of the trap unit 30 and the first surface 33 or the second surface 34 of the molded body are connected. A method of closely attaching can be used.

Instead of the inner wall of the body portion 301 and the bottom surface 302, the trap unit 30 may be a double of the outer cylinder and the inner cylinder, and the side surface of the molded body may be in close contact with the side surface of the inner cylinder. In this case, the urine flowing into the trap unit 30 passes between the outer cylinder and the inner cylinder and enters under the medicine 30. The urine that can no longer be stored in the trap unit 30 is discharged from a discharge portion provided in the outer cylinder.

The present invention will be specifically described based on the following examples, but the present invention is not limited to these examples.

(Example)
Benzoic acid, an acid, was used as the drug material. The benzoic acid used was ground to a particle size of about 100 μm. This was molded into a cylindrical shape by compression molding at a surface pressure of about 500 kg / cm ² to obtain a molded body.

In the cylindrical molded body thus obtained, the side surface and one of the circular surfaces were coated with a water-resistant material containing an epoxy resin with a thickness of about 2 mm by a brush coating method. This coated molded body was placed in a trap unit. At this time, the circular surface coated with the molded body was placed in close contact with the bottom surface of the trap unit so that there was no gap.

(Comparative example)
A comparative drug was obtained in the same manner as in Example except that the surface of the molded body was not coated.

(An endurance test)
A flush toilet was used as the urinal. As the trap unit, the one obtained above was used. The test used wash water as urine to evaluate drug solubility in non-washable urinals. That is, the amount of washing water was approximated to the average amount of urination per adult male, and the washing frequency was set assuming a public toilet with relatively high use frequency. Specific test conditions are shown below. For 8 hours in a day, the use of the urinal was actually assumed, and the stop with the washing with the washing water was repeated. The cleaning conditions were 1.6 L / min for 8 seconds, and then the cleaning was stopped for 3 minutes and 28 seconds. Assuming that the number of daily use of the urinal was 133 times, washing and stopping were repeated 133 times under the above-mentioned conditions. The remaining 16 hours were assumed to be unused time zones when actually using a urinal, and the trap unit was filled with water and left in a state where the drug was completely immersed in water.

  The test results are shown in FIG. The horizontal axis represents the number of days, and the vertical axis represents the dissolution rate of benzoic acid contained in the drug. The dissolution rate of benzoic acid was determined as follows. In the durability test, the amount (mg) of benzoic acid contained in 1 ml of water in the trap unit immediately before resuming water flow was measured by ion chromatography. The amount of benzoic acid was calculated by measuring a sample with a known concentration under the same conditions and converting it from the peak area of the obtained chromatogram. The amount of benzoic acid obtained here was assumed to be dissolved in 16 hours, the amount of benzoic acid dissolved in 1 hour was calculated, and the value was taken as the dissolution rate of benzoic acid.

From this result, it can be seen that the dissolution rate gradually decreases in the comparative example. On the other hand, in an Example, the fall of a dissolution rate can be suppressed. As a result, the drug dissolution rate can be kept constant, and the drug effect can be obtained for a long time. By keeping the drug dissolution rate constant for a long period of time, it was possible to suppress the increase in pH in the trap and prevent the generation of ammonia odor and urine stone for a long period of time.

US: Urinal WL: Wall of toilet room WT: Piping 10: Urinal body 101: Nozzle cover 102: Human body detection sensor 103: Bowl portion 104: Standing wall portion 105: Bottom portion 106: Bottom opening 20: Sanitary maintenance device 201 : Control unit 202: Nozzle unit (liquid agent discharge means)
203: Bowl drying fan 30: Trap unit 301: Body 302: Bottom surface 303: Guide 31: Drug 32: Side surface 33: First surface 34: Second surface

Claims (6)

In a urinal with a trap unit that forms a sealed water with urine,
In the trap unit,
A solid drug containing a material that suppresses the production of urinary stones is placed,
The drug is
The first aspect;
A second surface facing the first surface;
A side surface connecting the outer periphery of the first surface and the second surface,
The urinal is characterized in that the side surface is covered with a water-insoluble material so that urine does not come into contact therewith. 2. The urinal according to claim 1, wherein the first surface or the second surface is covered with a water-resistant material. The urinal according to claim 1 or 2, wherein the shape of the medicine is a cylinder. The trap unit is made of a non-water-soluble material,
The urinal according to claim 2 or 3, wherein the side surface of the medicine and the first surface of the medicine or the second surface of the medicine are covered with the trap unit. The trap unit has a body portion and a bottom surface,
The side surface of the medicine is formed by the body of the trap unit.
The urinal according to any one of claims 2 to 4, wherein the first surface or the second surface of the medicine is covered with a bottom surface of the trap unit. In the trap unit that forms sealed water by urine,
In the trap unit,
A solid drug containing a material that suppresses the production of urinary stones is placed,
The drug is
The first aspect;
A second surface facing the first surface;
A side surface connecting the outer periphery of the first surface and the second surface,
The side surface is covered with a non-water-soluble material so as not to contact urine,
Trap unit.

Images